FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3017058488> ?p ?o ?g. }

• W3017058488 abstract "Objectives : For suppressing both viral and bacterial respiratory infections, we investigate the possibility of obtaining real effective minimal inhibitory concentration (MIC) of silver nanoparticles in various respiratory system target locations. Applications include (i) control local outbreaks of COVID-19 via early stage home treatment, and (ii) lower the risk of ventilator associated pneumonia (VAP) in hospital ICU. Our prime objective is to propose a first line intervention measure with the potential to suppress proliferation of the viral infection across the respiratory system, thereby giving more time for proper immune system response and lowering the risk for aggravation and spread of the infection. We further discuss the available credible evidence for human safety consideration, by inhalation delivery, for facilitating immediate clinical trials. In addition, we discuss possible manufacturing and commercial availability of the method elements for near term wide public usage. Method : Based on previously published experimental data, on the antiviral effectiveness of colloidal silver, we propose a model method and computation for achieving antiviral MIC of silver particles in various respiratory system locations, by: (a) analysing the nanoparticle size dependent required concentration. (b) computing the required aerosol delivery characteristics. In order to compute the require delivery dosage, we take into account deposition fraction losses and also inhalation time fraction of the normal breathing cycle. We evaluate independent targeting of: (i) the trachea-bronchial tree (mucus volume of about 1cc), and (ii) the alveoli (total mucus volume of about 10cc). Results : The dosage is highly sensitive to the silver nanoparticle size, with 3nm - 7nm being the optimal size. Effective antibacterial MIC 10 μg/ml is estimated, but for more certainty 25 μg/ml is a reasonable target concentration to achieve in the mucus fluid of the respiratory system. In particular, using colloidal silver of 5nm particles, delivering inhalation of standard 5μ diameter droplets aerosol (e.g., using off-the-shelf ultrasonic mesh nebulizers), we assert that sufficient MIC can be achieved with: (i) depositing a total of just 0.25cc of a 100ppm (μg/ml) source concentration in the bronchial tree, and (ii) depositing a total of 1cc of a 250ppm (μg/ml) source concentration in the lungs alveoli. Yet, after accounting for deposition losses and due to the fact that active inhalation time is just about 1/3 of the breathing cycle, we find that that practical effective MIC can be achieved by these aerosolising dosages: (a) for the upper airways and bronchial tree use 2cc of a 100 μg/ml colloidal silver source, while (b) for lungs alveoli delivery use 6cc of a 200 μg/ml colloidal silver source. This would be reduced by a factor 3 if a breath actuated ultrasonic nebulizer is used. Conclusions : We conclude that effective MIC is achievable, both in the bronchial tree and in the alveoli (though the specific aerosol prescription may differ). Since respiratory infections start most commonly in the upper airways, it would be best to use the presented method early on as a first line treatment to suppress the progression of the infection. The required formulations are presently not available on the market but are easy to mass produce OTC in principle. Using off-the-shelf ultrasonic nebulizers and providable OTC colloidal silver formulations, we posit that our suggested method can be used precautionarily at home by anyone feeling the early signs of a potential infection. In addition, due to the anti-bacterial properties of colloidal silver, our method can serve in hospital intensive care units (ICU) as a new standard of care prophylactic treatment for ventilator acquired pneumonia (VAP)." @default.
• W3017058488 created "2020-04-24" @default.
• W3017058488 creator A5067546003 @default.
• W3017058488 date "2020-03-28" @default.
• W3017058488 modified "2023-09-30" @default.
• W3017058488 title "Formulations for COVID-19 Early Stage Treatment via Silver Nanoparticles Inhalation Delivery at Home and Hospital" @default.
• W3017058488 cites W1995823206 @default.
• W3017058488 cites W1998944697 @default.
• W3017058488 cites W2005628229 @default.
• W3017058488 cites W2104154679 @default.
• W3017058488 cites W2121299720 @default.
• W3017058488 cites W2145617208 @default.
• W3017058488 cites W2167077438 @default.
• W3017058488 cites W2471786891 @default.
• W3017058488 cites W2746379171 @default.
• W3017058488 cites W2964993739 @default.
• W3017058488 cites W2972091128 @default.
• W3017058488 cites W2991537413 @default.
• W3017058488 doi "https://doi.org/10.14293/s2199-1006.1.sor-.pphbjeo.v1" @default.
• W3017058488 hasPublicationYear "2020" @default.
• W3017058488 type Work @default.
• W3017058488 sameAs 3017058488 @default.
• W3017058488 citedByCount "23" @default.
• W3017058488 countsByYear W30170584882020 @default.
• W3017058488 countsByYear W30170584882021 @default.
• W3017058488 countsByYear W30170584882022 @default.
• W3017058488 countsByYear W30170584882023 @default.
• W3017058488 crossrefType "posted-content" @default.
• W3017058488 hasAuthorship W3017058488A5067546003 @default.
• W3017058488 hasBestOaLocation W30170584881 @default.
• W3017058488 hasConcept C126322002 @default.
• W3017058488 hasConcept C177713679 @default.
• W3017058488 hasConcept C18903297 @default.
• W3017058488 hasConcept C2776954882 @default.
• W3017058488 hasConcept C2777312293 @default.
• W3017058488 hasConcept C2777914695 @default.
• W3017058488 hasConcept C2779134260 @default.
• W3017058488 hasConcept C3008058167 @default.
• W3017058488 hasConcept C42219234 @default.
• W3017058488 hasConcept C524204448 @default.
• W3017058488 hasConcept C534529494 @default.
• W3017058488 hasConcept C71924100 @default.
• W3017058488 hasConcept C86803240 @default.
• W3017058488 hasConceptScore W3017058488C126322002 @default.
• W3017058488 hasConceptScore W3017058488C177713679 @default.
• W3017058488 hasConceptScore W3017058488C18903297 @default.
• W3017058488 hasConceptScore W3017058488C2776954882 @default.
• W3017058488 hasConceptScore W3017058488C2777312293 @default.
• W3017058488 hasConceptScore W3017058488C2777914695 @default.
• W3017058488 hasConceptScore W3017058488C2779134260 @default.
• W3017058488 hasConceptScore W3017058488C3008058167 @default.
• W3017058488 hasConceptScore W3017058488C42219234 @default.
• W3017058488 hasConceptScore W3017058488C524204448 @default.
• W3017058488 hasConceptScore W3017058488C534529494 @default.
• W3017058488 hasConceptScore W3017058488C71924100 @default.
• W3017058488 hasConceptScore W3017058488C86803240 @default.
• W3017058488 hasLocation W30170584881 @default.
• W3017058488 hasOpenAccess W3017058488 @default.
• W3017058488 hasPrimaryLocation W30170584881 @default.
• W3017058488 hasRelatedWork W1877883789 @default.
• W3017058488 hasRelatedWork W2316236384 @default.
• W3017058488 hasRelatedWork W2360105122 @default.
• W3017058488 hasRelatedWork W2474749474 @default.
• W3017058488 hasRelatedWork W2518470441 @default.
• W3017058488 hasRelatedWork W2799739826 @default.
• W3017058488 hasRelatedWork W3094131409 @default.
• W3017058488 hasRelatedWork W3108471389 @default.
• W3017058488 hasRelatedWork W3167007397 @default.
• W3017058488 hasRelatedWork W4253808419 @default.
• W3017058488 isParatext "false" @default.
• W3017058488 isRetracted "false" @default.
• W3017058488 magId "3017058488" @default.
• W3017058488 workType "article" @default.